Aug 5, 2026 08:00PM
Jun 24, 2026 08:00PM
Jun 24, 2026 08:00PM
Jun 21, 2026 08:00PM
Jun 21, 2026 08:00PM
May 31, 2026 08:00PM
May 31, 2026 08:00PM 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherap
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 10, 2026 08:00PM
Mar 1, 2026 07:00PM
Jan 26, 2026 07:00PM
Oct 21, 2025 08:25PM Innovent Biologics partners with Takeda in $11.4 billion cancer drug deal
Oct 21, 2025 08:25PM
Sep 18, 2025 12:00AM
Sep 7, 2025 08:30PM
Sep 7, 2025 08:30PM
Aug 27, 2025 06:08AM
Aug 24, 2025 08:00PM
Aug 24, 2025 08:00PM Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
Aug 4, 2025 08:00PM
Aug 4, 2025 08:00PM
Jul 23, 2025 10:36AM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jun 30, 2025 12:04AM Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
Jun 15, 2025 08:00PM
Jun 4, 2025 08:23PM
Jun 3, 2025 08:00PM
Jun 2, 2025 09:00PM
Jun 1, 2025 08:00PM
May 31, 2025 09:39PM
Mar 30, 2025 09:19PM Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
Mar 26, 2025 06:21AM
Mar 18, 2025 08:57PM
Mar 18, 2025 08:55PM
Mar 2, 2025 07:00PM
Feb 16, 2025 07:00PM
Jan 15, 2025 07:00PM
Jan 2, 2025 07:00PM Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
Dec 20, 2024 07:10AM
Dec 15, 2024 06:57PM
Dec 15, 2024 06:55PM
Dec 8, 2024 07:00PM
Sep 3, 2024 08:00PM
Aug 28, 2024 06:37AM
Jul 5, 2024 04:30AM Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
Jul 1, 2024 08:00PM

328,138 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All